¹ØÓÚÂØ¿¨Ä¹ÑÓ»º°¢¶û´Äº£Ä¬²¡½øÕ¹µÄ²¿ÃÅ»úÖƵÄ˵Ã÷

ÓɽðÔó´óѧµÄҽѧ¡¢ÖÆÒ©ºÍ½¡¿µ¿ÆѧÑо¿ËùKenjiro Ono£¨Ð¡Ò°ÏͶþÀÉ£©½ÌÊÚÁìµ¼µÄÑо¿Ð¡×éÓëÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Öêʽ»áÉçºÏ×÷ £¬ÀûÓÃпª·¢µÄÂØ¿¨Ä¹Ïà¹Øµí·ÛÑùÂÑ°×-¦ÂÔ­ÏËά£¨Lec-PF£©ÕÉÁ¿ÏµÍ³Ö¤Ã÷ £¬Óë·Ç°¢¶û´Äº£Ä¬²¡¶ÔÕÕ×éÏà±È £¬°¢¶û´Äº£Ä¬²¡»¼Õß´ÓÇá¶ÈÈÏÖªÕÏ°­µ½Çá¶ÈºÍÖضȳմôµÄ¸÷¸ö½×¶ÎÄÔ¼¹ÒºÖеÄLec-PFŨ¶È¶¼ÓÐËùÉý¸ß¡£´ËÍâ £¬ÕâÏîÑо¿»¹·¢ÏÖ £¬ÄÔ¼¹ÒºÖÐ Lec-PFµÄŨ¶ÈÓë·´Ó³Éñ¾­±äÐÔµÄÉúÎï±êÖ¾ÎïÓÐÃ÷ÏÔµÄÏà¹ØÐÔ¡£

ÂØ¿¨Ä¹ÊÇÒ»ÖÖÆæÌصÄË«ÖØ×÷Óÿ¹Ìå £¬³ýÁËÇå³ý°ß¿éÍâ £¬»¹Ñ¡ÔñÐÔ½áºÏµí·ÛÑùÂÑ°×-¦ÂÔ­ÏËά£¨PF£© £¬ÊÇÖÎÁÆ°¢¶û´Äº£Ä¬²¡£¨AD£©ÒýÆðµÄÇá¶ÈÈÏÖªÕÏ°­ºÍÇá¶È°¢¶û´Äº£Ä¬²¡£¨Í³³ÆΪÔçÆÚAD£©»¼ÕßµÄÒ»ÖÖÒ©Îï¡£ÕâÏîÑо¿µÄ½á¹û±íÃ÷ £¬ÂØ¿¨Ä¹²¶×½µÄPF£¨Lec-PF£©´æÔÚÓÚ°¢¶û´Äº£Ä¬²¡»¼ÕßµÄÄÔ¼¹ÒºÖÐ £¬Lec-PFÊÇÒ»Ö־綾µÄ²¡ÀíÂÑ°× £¬»áµ¼ÖÂÉñ¾­ÍËÐÐÐԱ䡣ÕâÏîÑо¿½ÒʾÁËÂØ¿¨Ä¹¼õ»º°¢¶û´Äº£Ä¬²¡½øÕ¹µÄ²¿ÃÅ»úÖÆ¡£

»ùÓÚÕâЩ·¢ÏÖ £¬Î´À´¿ÉÄÜÔÚÂØ¿¨Ä¹ÖÎÁÆÇ°ºóÕÉÁ¿ÄÔ¼¹ÒºÖÐLec PFµÄŨ¶È £¬ÒÔÆÀ¹ÀÖÎÁÆЧ¹û¡£´ËÍâ £¬ÓÉÓÚÄÔ¼¹ÒºÖÐLec-PFµÄŨ¶ÈÓë×ÜtauºÍÉñ¾­¿ÅÁ£ÂÑ°×µÈÉñ¾­ÍËÐÐÐÔ±êÖ¾ÎïÃÜÇÐÏà¹Ø £¬Ô¤¼ÆÕâЩ·¢ÏÖÒ²¿ÉÓÃÓÚÔ¤²â°¢¶û´Äº£Ä¬²¡»¼ÕßµÄÔ¤ºó¡£

ÕâÏîÑо¿ÓÚ2025Äê1ÔÂ6ÈÕ18:30£¨ÃÀ¹ú¶«²¿³ß¶Èʱ¼ä£©·¢±íÔÚ¹ú¼ÊѧÊõÆÚ¿¯¡¶Annals of Neurology¡·µÄÍøÂç°æÉÏ¡£

Ñо¿Åä¾°ºÍÄ¿µÄ

µí·ÛÑùÂÑ°×¼¶Áª¼Ù˵ÊǹØÓÚAD²¡ÒòµÄÖ÷ÒªÀíÂÛ £¬¸Ã¼Ù˵ÈÏΪ¦Âµí·ÛÑùÂÑ°×£¨A¦Â£©ÔÚÉñ¾­ÔªÍâÒì³£¾Û¼¯ £¬ËæºóÐγÉtauÉñ¾­Ô­ÏËά²ø½á £¬¶ÔÉñ¾­ÔªÔì³ÉËðÉË £¬²¢µ¼Ö¼²²¡·¢×÷¡£Ô­ÏËάÐÎ̬µÄ¦Âµí·ÛÑùÂÑ°×±ÈÏËάºÍ°ß¿éÐÎ̬¸ü¾ßÉñ¾­¶¾ÐÔ £¬ºóÕßÊÇÒì³£¾Û¼¯A¦ÂµÄ×îºó½×¶Î £¬Òò´ËÈÏΪPF¿ÉÄܻᵼÖÂÉñ¾­ÍËÐÐÐԱ䣨²Î¿¼ÎÄÏ×£ºAmin LºÍHarris DA.2012£©¡£ÂØ¿¨Ä¹ÊÇÒ»ÖÖ¿¹µí·ÛÑùÂÑ°×-¦ÂÔ­ÏËά¿¹Ìå £¬×Ô2023ÄêÒÔÀ´Ò»Ö±ÓÃÓÚÖÎÁÆÔçÆÚAD¡£È»¶ø £¬´ËǰûÓйØÓÚÕÉÁ¿ÈËÀàÉúÎïÑù±¾ÖÐPFŨ¶ÈµÄ³ÂËß £¬¶øÇÒ×÷ΪÂØ¿¨Ä¹ÖÎÁưеãµÄPFÔÚÕû¸öADÁ¬ÐøÌåÖеÄÂþÑÜÇé¿öÉв»Çå³þ¡£

ÔÚÕâÏîÑо¿ÖÐ £¬Ñо¿Ð¡×éʹÓÃпª·¢µÄ¸ßÁéÃô¶ÈLec-PFÕÉÁ¿ÏµÍ³ £¬ÕÉÁ¿ÁËÁÙ´²Ç°AD¡¢ADÒýÆðµÄÇá¶ÈÈÏÖªÕÏ°­ºÍAD³Õ´ôÊÜÊÔÕßÒÔ¼°SNAP£¨ÒÉËÆ·ÇAD²¡ÀíÉúÀíѧ£©»¼ÕߺÍÈÏÖª¹¦Ð§Õý³£ÕßµÄÈËÄÔ¼¹Òº£¨CSF£©ÖÐLec-PFµÄŨ¶È £¬²¢·ÖÎöÁËLec-PFÓëA¦Â40¡¢A¦Â42Á׵ĹØϵ¡¢ ²¢·ÖÎöÁËLec-PFÓëA¦Â40¡¢A¦Â42¡¢Á×Ëữtau£¨p-tau£©181£¨*9£©¡¢p-tau 217¡¢×ÜtauºÍÉñ¾­Á£ÂÑ°×Ö®¼äµÄ¹Øϵ¡£

Ñо¿½á¹û×ÛÊö

ADÒýÆðµÄÇá¶ÈÈÏÖªÕÏ°­»ò³Õ´ô»¼Õߣ¨Í¼1ÖеÄMCI+¡¢AD+×飩µÄLec PF CSFŨ¶ÈÃ÷ÏÔ¸ßÓÚÈÏÖª¹¦Ð§Õý³£µÄ»¼Õߣ¨Í¼ÖеÄYNCºÍAMC×飩¡£

¶ÔÄÔ¼¹ÒºÖÐLec-PFµÄŨ¶ÈÓëÆäËûÄÔ¼¹Òº±êÖ¾ÎA¦Â42¡¢A¦Â42/40±ÈÖµ¡¢p-tau 181¡¢p-tau217¡¢×Ütau¡¢Éñ¾­¿ÅÁ£ÂÑ°×£©Ö®¼ä½øÐÐÁËÏà¹ØÐÔ·ÖÎö¡£Í¼2ÏÔʾÁËLec PFºÍÖÖÖÖCSF±êÖ¾ÎïÖ®¼äµÄSpearmanÏà¹ØϵÊý£¨95%ÖÃÐÅÇø¼ä£©¡£ÔÚËùÓÐÊÜÊÔÕßÖУ¨Í¼2ÖеĺÚÏߣ© £¬ÄÔ¼¹ÒºÖÐLec PFŨ¶ÈÓëa¦Â42¡¢a¦Â42/40±ÈÖµ¡¢p-tau 181¡¢p-tau217¡¢×ÜtauºÍÉñ¾­¿ÅÁ£ÂѰ׳ÊÏà¹ØÐÔ £¬SpearmanϵÊýΪ0.2»ò¸ü¸ß¡£ÖµµÃ×¢ÒâµÄÊÇ £¬µ±½ö¹Ø×¢A¦ÂÑôÐÔ×éʱ£¨Í¼2ÖеĺìÏߣ© £¬Lec PFÓë×ÜtauºÍÉñ¾­¿ÅÁ£ÂÑ°×£¨A¦Â¼¶ÁªÖÐA¦ÂÏÂÓεÄÉñ¾­ÍËÐÐÐÔ±êÖ¾ÎÌåÏÖ³öºÜÇ¿µÄÏà¹ØÐÔ£¨SpearmanϵÊýΪ0.4»ò¸ü¸ß£© £¬ÕâÊÇADµÄ²¡Àíѧ¸Ä±ä £¬±íÃ÷Lec PFÊÇÒ»ÖÖÓëÉñ¾­ÍËÐÐÐÔ¼²²¡Ïà¹ØµÄ¾ç¶¾²¡ÀíÂѰס£

δÀ´Éú³¤

ÔÚÂØ¿¨Ä¹ÖÎÁÆÇ°ºóÕÉÁ¿CSFÖеÄLec-PFŨ¶È¿ÉÄÜÓÐÖúÓÚÆÀ¹ÀÂØ¿¨Ä¹ÖÎÁƵÄÁÆЧ¡£´ËÍâ £¬ÓÉÓÚCSFÖÐLec-PFµÄŨ¶ÈÓëÉñ¾­ÍËÐÐÐÔ±êÖ¾ÎïÃÜÇÐÏà¹Ø £¬Òò´ËËüÒ²¿ÉÄÜÓÐÖúÓÚÔ¤²âAD»¼ÕßµÄÔ¤ºó¡£

±¾Ñо¿»ñµÃÁËÈÕ±¾Ò½Ñ§Ñо¿¿ª·¢»ú¹¹£¨AMED£©³Õ´ôÖ¢Ñо¿ÓëÉú³¤×ÊÖú£¨×ÊÖúºÅ22dk0207053£©¡¢×ªÐÍÑо¿×ÊÖú£¨×ÊÖú±àºÅ23H03850£©ºÍ¿ÆѧÑо¿×ÊÖú£¨Åú×¼ºÅJP19k07965¡¢JP22k07514£©µÈÏîÄ¿µÄÖ§³Ö¡£

ͼ 1 ƾ¾ÝÁÙ´²Õï¶ÏºÍµí·ÛÑùÂÑ°×ÑôÐÔ/ÒõÐÔ·ÖÀàµÄÄÔ¼¹ÒºÂØ¿¨Ä¹Ïà¹Øµí·ÛÑùÂÑ°×Ô­ÏËά£¨CSF Lec-PF£©Å¨¶È

ÀûÀ´w66(ÖйúÇø)_À´Àû¹ú¼ÊÆì½¢

ͼ 1 ˵Ã÷

·½¿òͼÖеķ½¿òÌåÏÖËÄ·ÖλÊý¼ä¾à £¬Ë®Æ½ÏßÌåÏÖÖÐλÊý¡£¸÷×éËõд£º YNC£¨ÄêÇáÕý³£¶ÔÕÕ×éµí·ÛÑùÂÑ°×ÒõÐÔ£©¡¢AMC£¨ÄêÁäÆ¥Åä¶ÔÕÕ×éµí·ÛÑùÂÑ°×ÒõÐÔ£©¡¢CI-£¨ÈÏÖª¹¦Ð§ÊÜËð×éµí·ÛÑùÂÑ°×ÒõÐÔ£©¡¢CU+£¨ÈÏÖª¹¦Ð§Î´ÊÜËð×éµí·ÛÑùÂÑ°×ÑôÐÔ£©¡¢MCI+£¨Çá¶ÈÈÏÖª¹¦Ð§ÊÜËð×éµí·ÛÑùÂÑ°×ÑôÐÔ£©¡¢AD+£¨AD ³Õ´ô×éµí·ÛÑùÂÑ°×ÑôÐÔ£©¡¢CSF£¨ÄÔ¼¹Òº£©¡£

*p < 0.05

ͼ 2 ÄÔ¼¹Òº±êÖ¾ÎïÓëÄÔ¼¹ÒºÂØ¿¨Ä¹Ïà¹Øµí·ÛÑùÂÑ°×Ô­ÏËά£¨CSF Lec-PF£©µÄÏà¹ØÐÔ

ÀûÀ´w66(ÖйúÇø)_À´Àû¹ú¼ÊÆì½¢

ͼ2˵Ã÷

ºÚÏߺͺìÏß·Ö±ðÌåÏÖÕû¸öÊÜÊÔÕß×éºÍµí·ÛÑùÂÑ°×ÑôÐÔÊÜÊÔÕß×éCSF Lec-PFÓë¸÷ÄÔ¼¹Òº±êÖ¾ÎïÖ®¼ä˹Ƥ¶ûÂüÏà¹ØϵÊýµÄ95%ÖÃÐÅÇø¼ä (CI)¡£ºÚµãºÍºìµãÌåÏÖ˹Ƥ¶ûÂüÏà¹ØϵÊýµÄÖÐÖµ¡£ºÚÏߺͺìÏßÖ®¼äµÄ¾Þ´ó²îÒì·´Ó³ÁËA¦Â ÑôÐÔ»òÒõÐÔ״̬µÄÏÔÖøÓ°Ïì¡£

ÔÚÕâÏî·ÖÎöÖÐ £¬ËùÓÐÊÜÊÔÕߣ¨ºÚÏߣ©µÄCSF Lec-PFÓëËùÓвⶨµÄÉúÎï±êÖ¾Î¼´A¦Â42¡¢A¦Â42/40±ÈÖµ¡¢p-tau 181¡¢p-tau 217¡¢×Ü-tauºÍÉñ¾­¿ÅÁ£ÂÑ°×£©Ö®¼äµÄÏà¹ØϵÊý¾ùΪ0.2»ò¸ü¸ß £¬±íÃ÷ CSF Lec-PF ÓëÕâЩÉúÎï±êÖ¾ÎïÖ®¼ä´æÔÚÏÔÖøÏà¹ØÐÔ¡£ÔÚµí·ÛÑùÂÑ°×ÑôÐÔ×飨ºìÏߣ©ÖÐ £¬CSF Lec-PFÓëCSF total-tauµÄSpearmanÏà¹ØϵÊý·Ö±ðΪ0.634£¨CI£º0.409-0.786£© £¬CSF Lec-PFÓëCSF neurograninµÄSpearmanÏà¹ØϵÊý·Ö±ðΪ0.434£¨CI£º0.260-0.581£© £¬±íÃ÷CSF Lec-PFÓëÕâÁ½ÖÖÉúÎï±êÖ¾ÎïÖ®¼ä´æÔÚºÜÇ¿µÄÏà¹ØÐÔ¡£ÁíÒ»·½Ãæ £¬CSF Lec-PFÓëÄÔA¦ÂÀÛ»ýÉúÎï±êÖ¾ÎïCSF A¦Â42ºÍCSF A¦Â42/40±ÈÖµÖ®¼äµÄÏà¹ØÐÔ¶¼Ïà¶Ô½ÏµÍ¡£Õâ±íÃ÷ £¬CSF Lec-PFµÄº¬Á¿ÓëÉñ¾­ÍËÐÐÐÔ±äµÄ¹Øϵ±È´óÄÔÖÐA¦ÂµÄ»ýÀÛ¸üΪÃÜÇС£

 

ÎÄÕ·¢ÐÄÇé¿ö£º

ÆÚ¿¯Ãû³Æ£ºAnnals of Neurology

ÎÄÕÂÌâÄ¿: Lecanemab-associated amyloid-¦Â protofibril in cerebrospinal fluid correlates with

biomarkers of neurodegeneration in Alzheimer¡¯s disease (Cerebrospinal fluid (CSF) lecanemab-associated amyloid protofibril concentrations correlate well with neurodegenerative biomarkers in AD)

×÷Õß: Moeko Noguchi-Shinohara, Kazuyoshi Shuta, Hidetomo Murakami, Yukiko Mori, Junji Komatsu, Chizuru Kobayashi, Steven Hersch, Kanta Horie, Kenjiro Ono

·¢±íÈÕÆÚ£ºJanuary 6, 2025 (US Eastern Standard Time).

DOI: 10.1002/ANA.27175

 

ÐÅÏ¢ÁªÂ磺

¡ö Regarding research content

Kanazawa University

Professor Kenjiro Ono

TEL: +81-(0)76-265-2292

Email: onoken@med.kanazawa-u.ac.jp

Associate Professor Moeko Shinohara

TEL: +81-(0)76-265-2292

Email: m-nohara@med.kanazawa-u.ac.jp

Eisai Co., Ltd.

Kanta Horie

E-mail: kanta_horie@eisai.com

¡ö Public Relations Officer

General Affairs Section, General Affairs Division, Medical, Pharmaceutical and Health Sciences

Administration Department, Kanazawa University

Rina Yamada

TEL: +81-(0)76-265-2109

E-mail: t-isomu@adm.kanazawa-u.ac.jp

Eisai Co., Ltd. PR Department

TEL: +81-(0)3-3817-5120

±àºÅ£ºECN2025-0002